Higher expression of the gamma-glutamyl transpeptidase-to-platelet ratio (GPR) was observed in chronic hepatitis B (CHB) and non-alcoholic fatty liver disease (NAFLD) patients and GPR could be used as a non-invasive marker to predict liver fibrosis and cirrhosis in CHB-NAFLD individuals [69]. This evidence concerns the gene ALDH18A1 and metabolic dysfunction-associated steatotic liver disease.